Disruptive diagnostic for bacterial infection directly from whole blood in patients with SEPSIS

Sepsis patients die while doctors wait days for blood culture results to identify the infection. The SepsiSTAT platform skips the culture step entirely, detecting bacteria and their antibiotic resistance directly from a patient's blood sample in hours instead of days. This matters because sepsis kills quickly, and the current standard of care forces clinicians to guess which antibiotics to use. Broad-spectrum antibiotics are often sub-optimal, can harm some patients, and their overuse drives antimicrobial resistance—a growing global threat. Previous attempts at direct-from-blood testing have failed to deliver a credible alternative to blood culture. If SepsiSTAT succeeds, it could transform how sepsis is managed in hospitals. Instead of waiting days for a diagnosis, clinicians would have actionable results within hours, allowing them to target antibiotics precisely to the pathogen. This would improve patient survival, reduce unnecessary antibiotic use, and make hospital care more efficient. The platform addresses a critical bottleneck in infection management—the diagnostic delay that currently forces treatment decisions to be made in the dark.